Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D2C7-IT + 2141-V11 in Recurrent Glioblastoma
NCT06455605Phase 1Recruiting
- Sponsor
- Istari Oncology
- Start
- Mar 2025
- Primary completion
- Jan 2029
- Modality
- scFv Fragments, Immunotoxins, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of D2C7-(scdsFv)-PE38KDEL and 2141-V11 in glioblastoma (GBM), sponsored by Istari Oncology. Primary endpoints: Safety at 5 years and Efficacy at 6 years. Started Mar 2025; status: recruiting.
02
Drugs
D2C7-(scdsFv)-PE38KDEL2141-V11
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06455605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455605.